Last updated: September 9, 2026
Captopril-hydrochlorothiazide is a mature fixed-dose antihypertensive combination with limited commercial growth potential. The product combines the ACE inhibitor captopril with the thiazide diuretic hydrochlorothiazide. Its branded commercial history is associated with Capozide, while current market economics are driven primarily by low-cost generic tablets.
The product has no meaningful biologic substitution risk, no current innovation cycle, and limited patent-based pricing protection. Revenue is likely concentrated among generic manufacturers and distributors rather than the original innovator. Future value depends on manufacturing efficiency, supply continuity, formulary access, and niche demand rather than premium pricing.
What is captopril-hydrochlorothiazide used for?
Captopril-hydrochlorothiazide is used to treat hypertension when monotherapy with either an ACE inhibitor or a diuretic does not provide adequate blood-pressure control. Captopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation. Hydrochlorothiazide promotes urinary sodium and fluid excretion.
The combination offers two complementary mechanisms:
| Component |
Pharmacologic class |
Commercial role |
| Captopril |
ACE inhibitor |
Reduces vasoconstriction and aldosterone activity |
| Hydrochlorothiazide |
Thiazide diuretic |
Reduces plasma volume and sodium retention |
| Fixed-dose tablet |
Combination antihypertensive |
Improves dosing convenience and reduces pill burden |
The product is an older therapy. Many prescribers now use newer ACE inhibitor combinations, angiotensin-receptor blocker combinations, calcium-channel-blocker combinations, or single-pill products with stronger formulary support.
What is the FDA regulatory status of captopril-hydrochlorothiazide?
Captopril-hydrochlorothiazide was approved through the FDA new drug application pathway as an antihypertensive combination. Capozide was marketed by Bristol-Myers Squibb and supplied in multiple captopril and hydrochlorothiazide strengths. Historical product labeling identifies tablet strengths including 25/15 mg, 25/25 mg, 50/15 mg, and 50/25 mg, although commercial availability can vary by manufacturer and time period.[1]
The regulatory profile is now generic:
| Regulatory issue |
Current commercial significance |
| Original NDA |
Historical origin of the fixed-dose product |
| ANDA pathway |
Primary route for generic competition |
| FDA therapeutic class |
ACE inhibitor plus thiazide diuretic |
| Prescription status |
Prescription-only medicine |
| Biosimilar pathway |
Not applicable |
| Pediatric exclusivity |
No current commercial relevance |
| Orphan-drug status |
Not applicable |
| New chemical entity exclusivity |
Expired |
FDA-approved generic availability does not guarantee continuous supply. Older combination products are vulnerable to manufacturer discontinuations, raw-material constraints, low margins, and limited commercial interest in maintaining multiple strengths.
Is Capozide still a major branded product?
No. Capozide is a historical brand rather than a major current growth product. Even if a branded or authorized product remains listed in certain markets, the economic center of gravity is generic captopril-hydrochlorothiazide.
The brand has limited ability to command a premium because:
- The active ingredients are long established.
- Physicians have many substitute antihypertensive combinations.
- Generic versions are available.
- Payers generally place the product in low-cost formulary tiers.
- Switching costs are low for most patients.
- No current patent-based exclusivity supports premium pricing.
When does captopril-hydrochlorothiazide lose exclusivity?
The key composition and product exclusivity periods for captopril and the fixed-dose combination expired long ago. Captopril was first commercialized in the 1980s, and hydrochlorothiazide had already been used for decades. Any original patent protection would have ended many years ago under the standard U.S. patent term framework.
The practical exclusivity timeline is:
| Period |
Market status |
| 1980s |
Original branded fixed-dose combination commercialization |
| Late 1980s to 1990s |
Generic entry and erosion of branded exclusivity |
| 2000s |
Mature generic market with limited differentiation |
| 2010s |
Continued price competition and reduced brand relevance |
| 2020s |
Low-growth, low-price generic category |
Patent expiration is not the same as product discontinuation. A product may remain FDA-approved after a brand exits the market, provided an approved generic manufacturer continues to supply it.
What patents protect captopril-hydrochlorothiazide?
No commercially important original patent exclusivity is expected to remain for the basic captopril-hydrochlorothiazide combination. The original active ingredients are off-patent, and the basic fixed-dose concept is established technology.
Potential patent categories include:
- Composition patents covering captopril or hydrochlorothiazide.
- Combination patents covering use of the two active ingredients.
- Formulation patents covering tablet stability, excipients, or manufacturing processes.
- Method-of-use patents covering treatment of hypertension or related cardiovascular conditions.
- Manufacturing patents covering synthesis, purification, crystallization, or scale-up.
These categories have different commercial value. A manufacturing patent may create a supply advantage without preventing competitors from selling the finished product. A method-of-use patent has limited value where the claimed indication is already established and physicians can prescribe therapeutically equivalent alternatives.
How strong is the patent estate?
The patent estate is weak from a current commercial perspective.
| Patent factor |
Assessment |
| Basic active ingredients |
Expired |
| Fixed-dose combination |
Mature and readily substitutable |
| Orange Book leverage |
Limited or absent for current generic competition |
| Formulation protection |
Potentially narrow and likely expired or nonblocking |
| Manufacturing protection |
Possible but generally nonexclusive at the product level |
| Regulatory exclusivity |
Expired |
| Litigation leverage |
Low |
| Ability to support premium pricing |
Very low |
The absence of meaningful exclusivity does not eliminate all intellectual-property risk. Generic manufacturers can still face process-patent disputes, trade-secret allegations, quality claims, or contractual disputes. Those risks are separate from a blocking patent estate for the marketed tablet.
What is the Orange Book status of captopril-hydrochlorothiazide?
The FDA Orange Book is the controlling source for current listed patents, therapeutic-equivalence codes, and marketing status. For an old generic combination, the relevant commercial questions are whether an NDA or ANDA is active, whether a product is listed as discontinued, and whether any patent or exclusivity entry remains.
The expected Orange Book profile is:
- No meaningful remaining new chemical entity exclusivity.
- No biosimilar listing because the product is a small-molecule drug.
- Generic products, where approved and marketed, evaluated through the ANDA pathway.
- Any discontinued branded listing does not itself establish a safety withdrawal.
- Current availability may differ by strength and manufacturer.
Orange Book status should be evaluated at the product and strength level. A manufacturer may retain approval for a 25/25 mg tablet while discontinuing another strength. Approved status also does not establish active commercial distribution.
Are there Paragraph IV challenges for captopril-hydrochlorothiazide?
Paragraph IV litigation is unlikely to have current strategic importance because the core patents are long expired. Paragraph IV certifications matter when a generic applicant challenges an unexpired listed patent. For captopril-hydrochlorothiazide, the main generic-entry contest occurred historically, when the product transitioned from branded to generic supply.
Any current ANDA activity would more likely concern:
- Reentry after a manufacturing discontinuation.
- A new supplier seeking approval for an underserved strength.
- Product-specific bioequivalence or chemistry, manufacturing, and controls issues.
- A revised formulation or packaging configuration.
- Competition for a low-value market with intermittent shortages.
There is no apparent basis for a current, high-value Paragraph IV event comparable to litigation involving patented oncology, immunology, or diabetes products.
What formulations are protected by captopril-hydrochlorothiazide patents?
The commercially relevant formulation is an immediate-release oral tablet. It does not have the complex delivery architecture associated with extended-release products, injectable biologics, inhaled systems, or transdermal products.
Possible formulation issues include:
- Captopril stability and sensitivity to degradation.
- Moisture control and packaging.
- Compatibility between captopril and hydrochlorothiazide.
- Tablet hardness and dissolution.
- Excipient selection.
- Bioequivalence across strengths.
- Manufacturing controls for content uniformity.
These issues can create technical barriers without creating durable market exclusivity. The formulation is comparatively straightforward for an experienced generic manufacturer. Packaging and stability requirements may affect cost, but they are unlikely to support a durable premium.
What generic entry risks exist?
The principal risk is not a sudden patent-triggered launch. It is gradual margin compression combined with supply instability.
Price erosion
Generic antihypertensive combinations generally face rapid price competition once several suppliers are established. Pharmacy benefit managers and wholesalers can shift volume toward the lowest-cost source. Manufacturer profitability depends on scale, procurement, and reliable supply.
Product discontinuation
Low-volume strengths can become commercially unattractive. If several manufacturers leave the market, the remaining suppliers may obtain temporary pricing improvement, but that benefit can be offset by higher production and compliance costs.
Therapeutic substitution
Clinicians can substitute other ACE inhibitor/thiazide products or use separate tablets. Lisinopril-hydrochlorothiazide and enalapril-hydrochlorothiazide are examples of competing ACE inhibitor/thiazide combinations. Losartan-hydrochlorothiazide and valsartan-hydrochlorothiazide compete from the angiotensin-receptor blocker class.
Clinical tolerability
Captopril requires more frequent dosing than many newer ACE inhibitors and is associated with adverse effects such as cough, hyperkalemia, renal-function changes, and, rarely, angioedema. Hydrochlorothiazide adds electrolyte and metabolic monitoring requirements. These factors can reduce demand relative to newer single-pill regimens.
How does captopril-hydrochlorothiazide compare with competing drugs?
| Product category |
Competitive position versus captopril-hydrochlorothiazide |
| Lisinopril-hydrochlorothiazide |
Stronger contemporary prescribing position and broader generic familiarity |
| Enalapril-hydrochlorothiazide |
Similar older ACE inhibitor combination |
| Losartan-hydrochlorothiazide |
Useful alternative when ACE inhibitor cough is a concern |
| Valsartan-hydrochlorothiazide |
Established ARB combination with broader modern use |
| ACE inhibitor plus calcium-channel blocker |
Often preferred where cardiovascular-risk reduction and tolerability favor the regimen |
| Separate captopril and hydrochlorothiazide tablets |
Flexible dosing but less convenient than a fixed-dose tablet |
Captopril-hydrochlorothiazide retains utility where clinicians value captopril familiarity, low acquisition cost, or a specific historical treatment protocol. It lacks a strong differentiation platform.
What is the financial trajectory for captopril-hydrochlorothiazide?
Public companies generally do not report revenue for captopril-hydrochlorothiazide as a separate product. Financial analysis therefore must rely on product age, generic competition, prescription volume, reimbursement, and supply conditions.
The likely trajectory is:
| Financial phase |
Expected economics |
| Branded launch |
High relative price and innovator margin |
| Initial generic entry |
Rapid unit-price decline |
| Mature generic period |
High volume but low per-unit revenue |
| Consolidated supply period |
Possible short-term price increases during shortages |
| Long-term market |
Flat or declining revenue, with intermittent supply-driven volatility |
For a generic manufacturer, the opportunity is operational rather than innovation-driven. Profitability can come from:
- Low-cost active pharmaceutical ingredient sourcing.
- High plant utilization.
- Efficient packaging and distribution.
- Reliable supply to wholesalers and government buyers.
- Maintaining multiple strengths with shared manufacturing processes.
- Avoiding quality-related supply interruptions.
Revenue exposure for an individual manufacturer is likely modest unless it holds a large share of a concentrated supply market. Portfolio-level value may still exist because the product can generate recurring cash flow with limited commercial spending.
What could improve revenue?
Revenue could temporarily improve if:
- Competitors discontinue a strength.
- A manufacturing shortage restricts supply.
- A supplier obtains preferred formulary or tender placement.
- A manufacturer acquires an established generic portfolio.
- Demand rises in price-sensitive markets with limited access to newer combinations.
These factors support episodic pricing improvement, not a durable growth thesis.
What could reduce revenue?
Revenue pressure could increase through:
- Additional generic entrants.
- Pharmacy substitution toward separate low-cost tablets.
- Prescriber migration to lisinopril or ARB combinations.
- Hospital and government tender losses.
- Product recalls or manufacturing interruptions.
- Reduced demand for captopril because of dosing frequency and tolerability.
What licensing deals affect captopril-hydrochlorothiazide?
No major current licensing event is central to the product’s valuation. The original branded product was commercialized through the innovator’s own product portfolio. The present market is more likely to involve:
- Generic supply agreements.
- Contract manufacturing arrangements.
- Authorized-generic distribution.
- Regional marketing rights.
- Portfolio acquisitions involving multiple mature products.
A license covering only captopril-hydrochlorothiazide would have limited value unless it included a scarce manufacturing capability, a protected geographic market, or a broader antihypertensive portfolio.
What patent litigation and settlements affect the product?
Current high-value patent litigation appears unlikely. The product’s age and generic status reduce the probability of a new blocking-patent dispute. Historical generic-entry disputes may have occurred during the transition from branded to generic supply, but they would not normally affect present-day valuation unless they created enforceable settlement restrictions or continuing supply obligations.
The main present-day legal risks are more likely to arise from:
- Product liability.
- FDA manufacturing compliance.
- Labeling and pharmacovigilance.
- Antitrust allegations involving generic pricing.
- Supply contracts.
- Quality deviations and recalls.
These risks can affect margins and availability without changing the underlying patent position.
Is there biosimilar risk for captopril-hydrochlorothiazide?
No. Captopril-hydrochlorothiazide is a small-molecule combination, not a biologic. Biosimilar competition under the Public Health Service Act does not apply. Competition occurs through abbreviated new drug applications, therapeutic-equivalence determinations, price competition, and pharmacy substitution.
What is the geographic coverage of the captopril-hydrochlorothiazide market?
The product is most commercially relevant in markets where:
- Generic antihypertensives dominate procurement.
- Older ACE inhibitors remain clinically accepted.
- Fixed-dose combinations are reimbursed.
- Manufacturing and distribution costs are low.
- Newer branded combinations have limited access.
The strongest commercial markets are unlikely to be the highest-income markets, where treatment has shifted toward newer combinations and single-pill regimens. The product can retain demand in price-sensitive markets, public-sector tenders, and regions with established familiarity with captopril.
Geographic revenue is constrained by local registration requirements, stability standards, packaging rules, tender systems, and the availability of local generic manufacturers.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are moderate but manageable. The main technical considerations are captopril stability, moisture exposure, impurity control, tablet uniformity, and validated dissolution performance. A manufacturer also needs reliable hydrochlorothiazide and captopril supply, compliant facilities, and a regulatory dossier supporting bioequivalence.
The barriers do not appear high enough to protect the market from established generic companies. They may, however, deter small suppliers that lack:
- Stability-testing infrastructure.
- Validated analytical methods.
- Reliable API procurement.
- FDA or equivalent regulatory manufacturing compliance.
- Sufficient scale to support low-margin products.
Key Takeaways
- Captopril-hydrochlorothiazide is a mature generic antihypertensive combination.
- Capozide is a historical brand, not a major current growth asset.
- Original composition, combination, and regulatory exclusivities expired long ago.
- Paragraph IV litigation and patent-based launch risk have limited current relevance.
- Biosimilar competition does not apply.
- Revenue is likely low, fragmented, and not separately disclosed by most manufacturers.
- Financial performance depends on unit volume, supply concentration, procurement contracts, and manufacturing cost.
- The strongest risks are price erosion, therapeutic substitution, product discontinuation, and supply interruption.
- The strongest commercial opportunity is operational efficiency in a stable, low-cost generic portfolio.
- The product has limited potential for premium pricing, licensing value, or patent-supported expansion.
FAQs
Is captopril-hydrochlorothiazide still commercially viable?
Yes, as a low-cost generic product. Its viability depends on manufacturing scale, demand for specific strengths, and continued supplier participation.
Does captopril-hydrochlorothiazide have a meaningful remaining patent life?
No meaningful original patent life is expected to remain for the basic active ingredients or fixed-dose combination.
Can a generic manufacturer obtain premium pricing for captopril-hydrochlorothiazide?
Only temporarily, usually when competitors exit or supply becomes constrained. A durable premium is unlikely.
Is captopril-hydrochlorothiazide interchangeable with lisinopril-hydrochlorothiazide?
No. Both are ACE inhibitor/thiazide combinations, but they contain different ACE inhibitors and require clinical prescribing decisions. Therapeutic similarity does not establish automatic product interchangeability.
Would a new extended-release version create a strong commercial opportunity?
Probably not without clinical differentiation, reimbursement support, or valid patent protection. The market has many low-cost antihypertensive alternatives, limiting the value of a reformulation alone.
References
-
U.S. Food and Drug Administration. (n.d.). Capozide-25 captopril and hydrochlorothiazide tablet prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. FDA.
-
World Health Organization. (2023). WHO guideline for the pharmacological treatment of hypertension in adults. World Health Organization.
